Sugi Predict

Sugi Predict / Targets / LDLR

LDLR

Low-density lipoprotein receptor · P01130 · LDLR on Sugi Atlas →

8,237 patent compounds predicted against LDLR, 5,834 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL5897773 SCHEMBL5897773 0.72 16/20
SCHEMBL5897731 SCHEMBL5897731 0.70 15/20
SCHEMBL5897132 SCHEMBL5897132 0.72 14/20
SCHEMBL5897099 SCHEMBL5897099 0.81 13/20
SCHEMBL5897001 SCHEMBL5897001 0.67 13/20
SCHEMBL5897810 SCHEMBL5897810 1.00 12/20
SCHEMBL2353921 SCHEMBL2353921 0.61 12/20
SCHEMBL2348552 SCHEMBL2348552 0.57 12/20
Eptifibatide Eptifibatide (SCHEMBL2830072) 0.56 12/20
SCHEMBL2966826 SCHEMBL2966826 1.00 11/20
SCHEMBL4945389 SCHEMBL4945389 0.54 11/20
SCHEMBL3950126 SCHEMBL3950126 0.51 11/20
SCHEMBL4615147 SCHEMBL4615147 0.55 10/20
Nilotinib Nilotinib (SCHEMBL2098626) 0.86 9/20
SCHEMBL1954660 SCHEMBL1954660 0.86 9/20
SCHEMBL3945617 SCHEMBL3945617 0.81 9/20
SCHEMBL3949771 SCHEMBL3949771 0.78 9/20
SCHEMBL2979358 SCHEMBL2979358 0.71 9/20
Eptifibatide Eptifibatide (SCHEMBL43237) 0.57 9/20
Eptifibatide Eptifibatide (SCHEMBL1649793) 0.57 9/20

Clinical trials — most relevant to LDLR by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
PCSK9 Inhibitor for Intracranial Atherosclerosis Related Acute Ischemic Stroke PHASE4NOT_YET_RECRUITING
Evaluation of Statin Mechanism Preventing Cardiovascular Disease by Post-hoc Analysis of Treating to New Targets Study PHASE4COMPLETED
Effect of Evolocumab on Vascular Function PHASE4COMPLETED
PCSK9 Inhibitor With Statin Therapy for Asymptomatic Intracranial Atherosclerosis PHASE4RECRUITING
PCSK 9 Inhibition as Secondary Prevention in Renal Transplant Patients PHASE3COMPLETED
Treatment of Severe Infection With Antihyperlipidemia Drug PHASE2/PHASE3UNKNOWN
Study in Participants With Homozygous Familial Hypercholesterolemia (HoFH) PHASE3COMPLETED
Treatment of Patients With Atherosclerotic Disease With Paclitaxel-associated to LDL Like Nanoparticles PHASE2/PHASE3UNKNOWN
A Safety and Efficacy Study of AEGR-733 to Treat Homozygous Familial Hypercholesterolemia (FH) PHASE3COMPLETED
Open Label Extension of ISIS 301012 (Mipomersen) to Treat Familial Hypercholesterolemia PHASE2COMPLETED
Atorvastatin, L-Carnitine and Non-Alcoholic Steatohepatitis PHASE2UNKNOWN
Exosome-based Nanoplatform for Ldlr mRNA Delivery in FH PHASE1NOT_YET_RECRUITING
A Study of STX-1150 in Participants With Elevated Low-Density Lipoprotein Cholesterol (LDL-C) PHASE1NOT_YET_RECRUITING
Ekvasis of Atorvastatin (Antorcin®) Treatment in Patients With Acute Cardiovascular Events nanCOMPLETED
Biomarker for Homozygous Familial Hypercholesterolemia (BioHoFH) nanWITHDRAWN
Targeting Risk Factors for Diabetes in Subjects With Normal Blood Cholesterol Using Omega-3 Fatty Acids nanRECRUITING
Sex Hormones and Blood PCSK9 Levels nanCOMPLETED
Cardiovascular Evaluation of Patients With High Cholesterol and Normal Volunteers nanCOMPLETED
Epidemiology of Atherosclerosis nanCOMPLETED
Impact of Optimal Pharmacotherapy on Lipid Profile and Qualitative Features of Atherosclerotic Plaques nanUNKNOWN
The Association of SAA With Apolipoprotein B Affects Cardiovascular Risk nanCOMPLETED
Influence of Simvastatin on Apolipoprotein B-100 (apoB-100) Secretion nanCOMPLETED
Mechanisms of Glucose Lowering Effect of Colesevelam HCl nanCOMPLETED
Screening Protocol for a Gene Therapy Trial in Subjects With Homozygous Familial Hypercholesterolemia nanCOMPLETED
Prospective Assessment of Atherosclerotic Cardiovascular Disease (ASCVD) Risk nanUNKNOWN
Regeneron 1331 Kinetics Sub-Study HoFH nanCOMPLETED
Assessing the Impact of Intensification of Lipid Lowering Therapy With Guidelines-based Evinacumab Administration on Coronary Plaque Volumes Measured by Coronary Computed Tomography Angiography (CCTA) in Patients With Homozygous Familial Hypercholesterolemia (HoFH) nanRECRUITING
EAS Familial Hypercholesterolaemia Studies Collaboration nanRECRUITING
In Vivo Metabolism of apoB-containing Lipoproteins in ANGPTL3 Deficient Subjects nanUNKNOWN
Impact of Subclinical Hypothyroidism on Liver Enzymes and Lipid Profile nanNOT_YET_RECRUITING

Related proteins — ESM-2 sequence neighbours (a LDLR binder may also engage these)

ProteinNameSimilarity
P01131 — 1.000 P01131 →
P35951 — 1.000 P35951 →
P35952 — 1.000 P35952 →
P98165 — 1.000 P98165 →
P35950 — 1.000 P35950 →
Q28832 — 0.999 Q28832 →
P20063 — 0.999 P20063 →
P98166 — 0.998 P98166 →
P98156 — 0.997 P98156 →
Q98931 — 0.996 Q98931 →
P98155 — 0.996 P98155 →
P35953 — 0.995 P35953 →
Q99087 — 0.993 Q99087 →
Q924X6 — 0.991 Q924X6 →
Q99088 — 0.991 Q99088 →
Q14114 — 0.989 Q14114 →
Q95ND4 — 0.987 Q95ND4 →
P07522 — 0.986 P07522 →
Q00968 — 0.985 Q00968 →
Q9BEA0 — 0.985 Q9BEA0 →
P01133 — 0.985 P01133 →
Q91ZX7 — 0.984 Q91ZX7 →
P01132 — 0.984 P01132 →
P78504 — 0.984 P78504 →
Q07954 — 0.984 Q07954 →
Q9VXM0 — 0.983 Q9VXM0 →
Q9NQ36 — 0.983 Q9NQ36 →
Q63722 — 0.983 Q63722 →
P98164 — 0.983 P98164 →
ST14 Suppressor of tumorigenicity 14 protein 0.982 landscape →